NVCT
Nuvectis Pharma, Inc.
Price Chart
Latest Quote
$17.29
+0.76 (+4.60%)
Current Price
| Previous Close | $16.53 |
| Open | $16.03 |
| Day High | $18.24 |
| Day Low | $15.88 |
| Volume | 192,514 |
Stock Information
| Shares Outstanding | 26.53M |
| Cash Equivalents | $25.13M |
| Net Income | $-29.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $458.63M |
| EPS (TTM) | $-1.31 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $413.34M |
| Income | $-29.59M |
| Book/sh | $0.54 |
| Cash/sh | $0.95 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 2.25 |
| Current Ratio | 2.27 |
Returns & Margins
| ROA | -63.61% |
| ROE | -154.43% |
Ownership
| Insider Ownership | 42.13% |
| Institutional Ownership | 18.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -18.01 |
| P/B | 32.26 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $26.60 |
Technical Indicators
| SMA20 | $11.10 |
| SMA50 | $10.24 |
| SMA200 | $8.10 |
| RSI | 94.82 |
| ATR | 1.0199 |
| Shares Float | 15.27M |
| Short Float | 10.14% |
| Short Ratio | 13.28 |
| Volatility | -0.07 |
| Rel Volume | 1.59 |
Performance History
| Week | +55.07% |
| Month | +58.04% |
| Quarter | +109.32% |
| 6 Months | +116.67% |
| YTD | +103.17% |
| Year | +112.67% |
| 3 Years | -5.00% |
| 10 Years | +432.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $17.29 | 192,514 |
| 2026-06-22 | $16.53 | 408,500 |
| 2026-06-18 | $13.82 | 323,300 |
| 2026-06-17 | $12.59 | 98,600 |
| 2026-06-16 | $11.94 | 215,100 |
| 2026-06-15 | $11.15 | 76,200 |
| 2026-06-12 | $10.71 | 69,100 |
| 2026-06-11 | $10.51 | 62,700 |
| 2026-06-10 | $10.31 | 100,100 |
| 2026-06-09 | $9.80 | 64,100 |
| 2026-06-08 | $9.42 | 41,400 |
| 2026-06-05 | $9.54 | 74,400 |
| 2026-06-04 | $9.67 | 38,100 |
| 2026-06-03 | $9.31 | 68,800 |
| 2026-06-02 | $9.51 | 76,100 |
| 2026-06-01 | $9.75 | 98,400 |
| 2026-05-29 | $9.75 | 105,400 |
| 2026-05-28 | $10.19 | 57,400 |
| 2026-05-27 | $10.15 | 126,400 |
| 2026-05-26 | $10.10 | 127,600 |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
đ° Latest News
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
InvestorsHub âĸ 2026-06-22T12:53:18Z
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
Zacks âĸ 2026-05-25T13:55:04Z
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
Zacks âĸ 2026-05-07T13:55:03Z
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma
Simply Wall St. âĸ 2026-05-04T10:36:30Z
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Simply Wall St. âĸ 2026-03-24T12:27:10Z
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders
Simply Wall St. âĸ 2025-12-05T12:15:29Z
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares
Simply Wall St. âĸ 2025-11-08T12:00:16Z
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2025-10-15T12:08:42Z
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure
Clinical Trials Arena âĸ 2025-08-04T11:41:35Z
Nuvectis Pharma Insiders Added US$2.50m Of Stock To Their Holdings
Simply Wall St. âĸ 2025-07-29T10:24:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $27,574,000 | $19,847,000 | $22,897,000 | $19,234,000 |
| Net Non Operating Interest Income Expense | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Operating Expense | $27,574,000 | $19,847,000 | $22,897,000 | $19,234,000 |
| General And Administrative Expense | $9,421,000 | $6,929,000 | $7,517,000 | $6,007,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Interest Income | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Interest Income | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Normalized Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income From Continuing And Discontinued Operation | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Total Operating Income As Reported | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Net Income Common Stockholders | $-28,871,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income Including Noncontrolling Interests | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Net Income Continuous Operations | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Pretax Income | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Interest Income Non Operating | $1,132,000 | $847,000 | $637,000 | $149,000 |
| Operating Income | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Per Share | ||||
| Diluted EPS | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Basic EPS | $-1.32 | $-1.11 | $-1.43 | $-1.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| EBITDA (Bullshit earnings) | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| EBIT | $-27,574,000 | $-19,847,000 | $-22,897,000 | $-19,234,000 |
| Diluted Average Shares | $21,812,716 | $17,113,169 | $15,556,655 | $12,657,651 |
| Basic Average Shares | $21,812,716 | $17,113,169 | $15,556,655 | $12,657,651 |
| Diluted NI Availto Com Stockholders | $-28,871,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Otherunder Preferred Stock Dividend | $2,429,000 | $0 | - | - |
| Research And Development | $18,153,000 | $12,918,000 | $15,380,000 | $13,227,000 |
| Selling General And Administration | $9,421,000 | $6,929,000 | $7,517,000 | $6,007,000 |
| Other Gand A | $6,401,000 | $4,232,000 | $4,377,000 | $3,068,000 |
| Insurance And Claims | $599,000 | $606,000 | $842,000 | $1,183,000 |
| Salaries And Wages | $2,421,000 | $2,091,000 | $2,298,000 | $1,756,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Assets | $31,709,000 | $18,607,000 | $19,185,000 | $20,405,000 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $31,709,000 | $18,607,000 | $19,185,000 | $20,405,000 |
| Other Current Assets | $75,000 | $74,000 | $59,000 | $412,000 |
| Cash Cash Equivalents And Short Term Investments | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Cash And Cash Equivalents | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Non Current Deferred Assets | - | - | - | $0 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,296,000 | $8,894,000 | $6,984,000 | $6,186,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $13,296,000 | $8,894,000 | $6,984,000 | $6,186,000 |
| Payables And Accrued Expenses | $6,389,000 | $3,338,000 | $3,186,000 | $3,805,000 |
| Payables | $6,274,000 | $2,498,000 | $2,771,000 | $3,360,000 |
| Accounts Payable | $6,274,000 | $2,498,000 | $2,771,000 | $2,910,000 |
| Other Payable | - | - | - | $450,000 |
| Equity | ||||
| Common Stock Equity | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Equity Gross Minority Interest | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Stockholders Equity | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Retained Earnings | $-99,687,000 | $-73,245,000 | $-54,245,000 | $-31,985,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $25,676,798 | $19,495,683 | $17,418,886 | $14,642,483 |
| Share Issued | $25,676,798 | $19,495,683 | $17,418,886 | $14,642,483 |
| Tangible Book Value | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Invested Capital | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Working Capital | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Total Capitalization | $18,413,000 | $9,713,000 | $12,201,000 | $14,219,000 |
| Additional Paid In Capital | $118,100,000 | $82,958,000 | $66,446,000 | $46,204,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,907,000 | $5,556,000 | $3,798,000 | $2,381,000 |
| Current Accrued Expenses | $115,000 | $840,000 | $415,000 | $445,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Cash Flow From Continuing Operating Activities | $-16,009,000 | $-12,247,000 | $-15,954,000 | $-13,559,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Financing Cash Flow | $29,110,000 | $11,654,000 | $15,087,000 | $27,810,000 |
| Cash Flow From Continuing Financing Activities | $29,110,000 | $11,654,000 | $15,087,000 | $27,810,000 |
| Net Other Financing Charges | $-2,100,000 | $-382,000 | $-1,394,000 | $-4,069,000 |
| Net Common Stock Issuance | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Common Stock Issuance | $31,210,000 | $12,036,000 | $5,289,000 | $31,879,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $31,634,000 | $18,533,000 | $19,126,000 | $19,993,000 |
| Beginning Cash Position | $18,533,000 | $19,126,000 | $19,993,000 | $5,742,000 |
| Changes In Cash | $13,101,000 | $-593,000 | $-867,000 | $14,251,000 |
| Change In Working Capital | $4,401,000 | $1,895,000 | $1,601,000 | $3,819,000 |
| Change In Other Working Capital | $1,351,000 | $1,758,000 | $1,417,000 | $1,951,000 |
| Change In Other Current Assets | $-1,000 | $-15,000 | $353,000 | $-321,000 |
| Change In Payables And Accrued Expense | $3,051,000 | $152,000 | $1,248,000 | $4,140,000 |
| Change In Accrued Expense | $-725,000 | $425,000 | $1,387,000 | $2,289,000 |
| Change In Payable | $3,776,000 | $-273,000 | $-139,000 | $1,851,000 |
| Change In Account Payable | $3,776,000 | $-273,000 | $-139,000 | $1,851,000 |
| Stock Based Compensation | $6,032,000 | $4,858,000 | $4,705,000 | $1,707,000 |
| Net Income From Continuing Operations | $-26,442,000 | $-19,000,000 | $-22,260,000 | $-19,085,000 |
| Proceeds From Stock Option Exercised | - | $0 | $11,192,000 | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-23